HK inno.N has reported promising results for its obesity treatment drug Ecnoglutide in a Phase 1b clinical trial involving obese adolescents. The study showed a maximum reduction of 12.6% in Body Mass Index (BMI) and up to 12.1% in body weight at the 20-week mark.

On Tuesday, HK inno.N announced that its Chinese partner, Sciwind Bioscience, presented these findings at the European Association for the Study of Diabetes (EASD) conference held in Milan, Italy, on September 30.

The trial included 48 Chinese adolescents aged 12 to 17 who were administered either 1.2 mg, 1.8 mg, or 2.4 mg of Ecnoglutide or a placebo over a 20-week treatment period.

At the 20-week mark, the Ecnoglutide group showed a BMI decrease of 11.2% to 12.6% from baseline, with weight reductions of 10.4% to 12.1%. In contrast, the placebo group showed no significant changes in BMI and experienced a slight weight increase of 1.2%. The statistical significance of the weight change was P

The study also revealed reductions in waist and neck circumferences for the Ecnoglutide group. Improvements were noted in key metabolic and cardiovascular indicators, including HbA1c, triglycerides, and blood pressure, compared to the placebo group.

HK inno.N has reported promising results for its obesity treatment drug Ecnoglutide in a P …

Ecnoglutide: The Breakthrough Obesity Treatment for Teens with Up to 12.6% BMI Reduction